HRP20180516T1 - Humanizirana protutijela specifična za protofibrilni oblik amiloidnog-beta peptida - Google Patents
Humanizirana protutijela specifična za protofibrilni oblik amiloidnog-beta peptida Download PDFInfo
- Publication number
- HRP20180516T1 HRP20180516T1 HRP20180516TT HRP20180516T HRP20180516T1 HR P20180516 T1 HRP20180516 T1 HR P20180516T1 HR P20180516T T HRP20180516T T HR P20180516TT HR P20180516 T HRP20180516 T HR P20180516T HR P20180516 T1 HRP20180516 T1 HR P20180516T1
- Authority
- HR
- Croatia
- Prior art keywords
- seq
- sequences
- sequence
- antibody
- antibody according
- Prior art date
Links
- 102000013455 Amyloid beta-Peptides Human genes 0.000 title 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 title 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims 7
- 229920001184 polypeptide Polymers 0.000 claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 239000002773 nucleotide Substances 0.000 claims 4
- 125000003729 nucleotide group Chemical group 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 208000037259 Amyloid Plaque Diseases 0.000 claims 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 2
- 239000012636 effector Substances 0.000 claims 2
- 102000018358 immunoglobulin Human genes 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 238000002965 ELISA Methods 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000012752 auxiliary agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (20)
1. Humanizirano protutijelo specifično za protofibrilni oblik A-β peptida, naznačeno time da:
- navedeno protutijelo ima smanjene efektorske funkcije,
- varijabilni dio njegovog teškog lanca sadrži sekvencu koja ima najmanje 90% identičnosti sa sekvencom SEQ ID NO: 6 ili SEQ ID NO: 28,
- varijabilni dio njegovog lakog lanca sadrži sekvencu koja ima najmanje 90% identičnosti sa sekvencom SEQ ID NO: 8 ili SEQ ID NO: 24,
- navedeno protutijelo ima afinitet za protofibrilni oblik Aβ peptida najmanje 100 puta veći od njegovog afiniteta za ostale oblike ovog peptida, te je afinitet EC50 mjeren pomoću ELISA; i
- navedeno protutijelo se veže na A-β peptide nakupljene u senilnim plakovima i ne na difuzne naslage A-β peptida.
2. Protutijelo prema zahtjevu 1, naznačeno time da navedeno protutijelo je imunoglobulin koji nosi mutacije Fc domene smanjujući njegov afinitet za receptore imunološkog sustava.
3. Protutijelo prema zahtjevu 1 ili 2, naznačeno time da navedeno protutijelo je imunoglobulin G4 čija je Fc domena podvrgnuta mutacijama koje smanjuju efektorsku aktivnost.
4. Protutijelo prema bilo kojem od prethodnih zahtjeva, naznačeno time da sadrži barem jednu CDR kodiranu sa nukleotidnom sekvencom koja ima sekvencu identičnu jednoj od sekvenci SEQ ID NO: 9, 11, 13, 15, 17 i 19, ili sa sekvencama koje se razlikuju po 1, 2, 3, 4 ili 5 nukleotida iz ovih sekvenci.
5. Protutijelo prema bilo kojem od prethodnih zahtjeva, naznačeno time da sadrži barem jednu CDR koja ima sekvencu identičnu jednoj od sekvenci SEQ ID NO: 10, 12, 14, 16, 18 i 20.
6. Protutijelo prema bilo kojem od prethodnih zahtjeva, naznačeno time da sadrži barem jednu CDR čija se sekvenca razlikuje za jednu do dvije aminokiseline u odnosu na jednu od sekvenci SEQ ID NO: 10, 12, 14, 16, 18 i 20, pod uvjetom da protutijelo održava svoju specifičnost vezanja.
7. Protutijelo prema bilo kojem od prethodnih zahtjeva, naznačeno time da sadrži CDR-ove kodirane sa (i) nukleotidnim sekvencama SEQ ID NO: 9, 11, 13, 15, 17 i 19, (ii) nukleotidnim sekvencama SEQ ID NO: 9, 11, 13, 31, 17 i 19, (iii) nukleotidnim sekvencama SEQ ID NO: 9, 11, 29, 31, 17 i 19, ili sa sekvencama koje se razlikuju po 1, 2, 3, 4 ili 5 nukleotida iz ovih sekvenci.
8. Protutijelo prema bilo kojem od prethodnih zahtjeva, naznačeno time da sadrži CDR-ove za sekvence SEQ ID NO: 10, 12, 14, 16, 18 i 20, CDR-ove za sekvence SEQ ID NO: 10, 12, 14, 32, 18 i 20, ili CDR-ove za sekvence SEQ ID NO: 10, 12, 30, 32, 18 i 20.
9. Protutijelo prema bilo kojem od prethodnih zahtjeva, naznačeno time da:
- varijabilni dio njegovog teškog lanca je kodiran sekvencom koja barem 80% identičnosti s jednom od sekvenci SEQ ID NO: 5 i SEQ ID NO:27,
- varijabilni dio njegovog lakog lanca je kodiran sekvencom koja ima barem 80% identičnosti s jednom od sekvenci SEQ ID NO: 7 i SEQ ID NO: 23,
- sadrži teški lanac kojeg kodira sekvenca koja ima barem 80% identičnosti s jednom od nukleotidnih sekvenci SEQ ID NO: 1 i SEQ ID NO: 25 i/ili teški lanac koji ima barem 80% identičnosti s jednom od polipeptidnih sekvenci SEQ ID NO: 2 i SEQ ID NO: 26, i/ili
- sadrži lagani lanac kojeg kodira sekvenca koja ima barem 80% identičnosti s jednom od nukleotidnih sekvenci SEQ ID NO: 3 i SEQ ID NO: 21 i/ili lagani lanac koji ima barem 80% identičnosti s jednom od polipeptidnih sekvenci SEQ ID NO: 4 i SEQ ID NO: 22.
10. Protutijelo prema bilo kojem od prethodnih zahtjeva, naznačeno time da:
- sadrži sekvence kodirane sa (i) nukleotidnim sekvencama SEQ ID NO: 5 i 7, (ii) nukleotidnim sekvencama SEQ ID NO: 5 i 23 ili (iii) nukleotidnim sekvencama SEQ ID NO: 27 i 23, i/ili sekvence kodirane sa (i) nukleotidnim sekvencama SEQ ID NO: 1 i 3, (ii) nukleotidnim sekvencama SEQ ID NO: 1 i 21 ili (iii) nukleotidnim sekvencama SEQ ID NO: 25 i 21, i/ili
- njegova sekvenca obuhvaća polipeptidne sekvence (i) SEQ ID NO: 6 i 8, (ii) SEQ ID NO: 6 i 24, ili (iii) SEQ ID NO: 28 i 24, i/ili polipeptidne sekvence (i) SEQ ID NO: 2 i 4, (ii) SEQ ID NO: 2 i 22, (iii) SEQ ID NO: 26 i 22.
11. Protutijelo prema bilo kojem od prethodnih zahtjeva, naznačeno time da inducira smanjenje amiloidnih plakova.
12. Protutijelo prema bilo kojem od zahtjeva 1 do 11, naznačeno time da je za uporabu za liječenje bolesti povezanih s neurodegenerativnim poremećajima.
13. Protutijelo za uporabu prema zahtjevu 12, naznačeno time da je za liječenje Alzheimerove bolesti.
14. Farmaceutski pripravak naznačen time da sadrži protutijelo prema bilo kojem od zahtjeva 1 do 11 i pomoćna sredstva.
15. Stanica naznačena time da proizvodi protutijelo prema bilo kojem od zahtjeva 1 do 11.
16. Postupak za proizvodnju protutijela prema bilo kojem od zahtjeva 1 do 11, naznačen time da obuhvaća kultiviranje stanica prema zahtjevu 15.
17. Protutijelo prema bilo kojem od zahtjeva 1 do 11 naznačeno time da je namijenjeno upotrebi kao lijek.
18. Polinukleotid eksprimira protutijelo prema bilo kojem od zahtjeva 1 do 11, naznačen time da navedeni polinukleotid kodira polipeptid koji ima najmanje 90% identičnosti s jednom od sekvenci SEQ ID NOS: 2, 4, 6, 8, 22, 24, 26 ili 28, ili ima sekvencu koja ima najmanje 90% identičnosti s jednom od sekvenci SEQ ID NOS: 1, 3, 5, 7, 21, 23, 25 ili 27.
19. Rekombinantni vektor naznačen time da sadrži nukleinsku kiselinu prema zahtjevu 18.
20. Stanica domaćin naznačena time da sadrži vektor prema zahtjevu 19.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0953133A FR2945538B1 (fr) | 2009-05-12 | 2009-05-12 | Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide. |
| EP15160538.3A EP2977385B1 (fr) | 2009-05-12 | 2010-05-11 | Anticorps humanises spécifiques de la forme protofibrillaire du peptide béta-amyloide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20180516T1 true HRP20180516T1 (hr) | 2018-05-04 |
Family
ID=41591699
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20150776TT HRP20150776T1 (hr) | 2009-05-12 | 2015-07-14 | Humanizirana protutijela koja su specifiäśna za protofibrilarni oblik beta-amiloidnog peptida |
| HRP20180516TT HRP20180516T1 (hr) | 2009-05-12 | 2018-03-27 | Humanizirana protutijela specifična za protofibrilni oblik amiloidnog-beta peptida |
| HRP20181985TT HRP20181985T1 (hr) | 2009-05-12 | 2018-11-27 | Humanizirana protutijela specifična za protofibrilarni oblik beta-amiloidnog peptida |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20150776TT HRP20150776T1 (hr) | 2009-05-12 | 2015-07-14 | Humanizirana protutijela koja su specifiäśna za protofibrilarni oblik beta-amiloidnog peptida |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20181985TT HRP20181985T1 (hr) | 2009-05-12 | 2018-11-27 | Humanizirana protutijela specifična za protofibrilarni oblik beta-amiloidnog peptida |
Country Status (42)
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2705582A1 (en) | 2007-11-16 | 2009-05-22 | The Rockefeller University | Antibodies specific for the protofibril form of beta-amyloid protein |
| AR085302A1 (es) | 2011-02-24 | 2013-09-18 | Sanofi Sa | Metodo de produccion de anticuerpos sialilados |
| JP2013159596A (ja) * | 2012-02-08 | 2013-08-19 | Nihon Univ | β−アミロイド前駆体タンパク質のマイクロ凝集体に特異的なモノクローナル抗体 |
| CA2904357C (en) | 2013-03-15 | 2020-09-22 | Intrinsic Lifesciences Llc | Anti-hepcidin antibodies and uses thereof |
| JP6669749B2 (ja) | 2014-08-08 | 2020-03-18 | アレクトル エルエルシー | 抗ｔｒｅｍ２抗体及びその使用方法 |
| NZ730186A (en) | 2014-09-22 | 2020-04-24 | Intrinsic Lifesciences Llc | Humanized anti-hepcidin antibodies and uses thereof |
| RS62546B1 (sr) | 2015-04-07 | 2021-12-31 | Alector Llc | Antitela protiv sortilina i postupci za njihovu upotrebu |
| WO2016201389A2 (en) | 2015-06-12 | 2016-12-15 | Alector Llc | Anti-cd33 antibodies and methods of use thereof |
| EP3307771A2 (en) | 2015-06-12 | 2018-04-18 | Alector LLC | Anti-cd33 antibodies and methods of use thereof |
| EP3325506A1 (en) | 2015-07-21 | 2018-05-30 | BioArctic AB | Method for treatment of traumatic brain injury targeting aggregated peptides |
| CN108137702B (zh) | 2015-08-28 | 2023-01-06 | 艾利妥 | 抗siglec-7抗体及其使用方法 |
| KR20180068999A (ko) | 2015-10-06 | 2018-06-22 | 알렉터 엘엘씨 | 항-trem2 항체 및 그의 사용방법 |
| US10800844B2 (en) | 2015-10-29 | 2020-10-13 | Alector Llc | Anti-Siglec-9 antibodies and methods of use thereof |
| US11472877B2 (en) | 2016-03-04 | 2022-10-18 | Alector Llc | Anti-TREM1 antibodies and methods of use thereof |
| JP2020500020A (ja) | 2016-11-14 | 2020-01-09 | ノバルティス アーゲー | 融合誘導性タンパク質ｍｉｎｉｏｎに関連する組成物、方法、および治療上の使用 |
| EP3354278A1 (en) * | 2017-01-31 | 2018-08-01 | Sanofi | Neuronal cell protective effect of antibodies specific for the protofibrillar form of the beta-amyloid peptide |
| WO2018213316A1 (en) | 2017-05-16 | 2018-11-22 | Alector Llc | Anti-siglec-5 antibodies and methods of use thereof |
| JP7299160B2 (ja) | 2017-08-03 | 2023-06-27 | アレクトル エルエルシー | 抗ｃｄ３３抗体及びその使用方法 |
| CR20190485A (es) | 2017-08-03 | 2020-02-10 | Alector Llc | Anticuerpos anti-trem2 y métodos para utilizarlos |
| MA52753A (fr) | 2018-05-25 | 2021-04-21 | Alector Llc | Anticorps anti-sirpa et leurs procédés d'utilisation |
| UY38247A (es) | 2018-05-30 | 2019-12-31 | Novartis Ag | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación |
| BR112020024919A2 (pt) | 2018-06-08 | 2021-03-09 | Alector Llc | Anticorpos, ácido nucleico, vetor, célula hospedeira, métodos de produção de um anticorpo e de prevenção, redução do risco ou tratamento de câncer e composição farmacêutica |
| HUE061841T2 (hu) | 2018-07-13 | 2023-08-28 | Alector Llc | Anti-sortilin antitestek és felhasználásuk módszerei |
| EP3830123A1 (en) | 2018-07-27 | 2021-06-09 | Alector LLC | Anti-siglec-5 antibodies and methods of use thereof |
| WO2020047374A1 (en) | 2018-08-31 | 2020-03-05 | Alector Llc | Anti-cd33 antibodies and methods of use thereof |
| UY38407A (es) | 2018-10-15 | 2020-05-29 | Novartis Ag | Anticuerpos estabilizadores de trem2 |
| TW202110878A (zh) | 2019-05-16 | 2021-03-16 | 法商賽諾菲公司 | 在神經系統中表現抗原結合蛋白 |
| KR20220032568A (ko) | 2019-06-25 | 2022-03-15 | 길리애드 사이언시즈, 인코포레이티드 | Flt3l-fc 융합 단백질 및 사용 방법 |
| WO2021035033A1 (en) * | 2019-08-20 | 2021-02-25 | The Curators Of The University Of Missouri | Amyloid-beta antibodies |
| TW202124446A (zh) | 2019-09-18 | 2021-07-01 | 瑞士商諾華公司 | 與ｅｎｔｐｄ２抗體之組合療法 |
| CN114502590A (zh) | 2019-09-18 | 2022-05-13 | 诺华股份有限公司 | Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法 |
| BR112022011337A2 (pt) | 2019-12-12 | 2022-08-23 | Alector Llc | Método para tratar e/ou retardar a progressão de uma doença ou lesão em um indivíduo |
| EP4204092A1 (en) | 2020-08-25 | 2023-07-05 | Gilead Sciences, Inc. | Multi-specific antigen binding molecules targeting hiv and methods of use |
| TW202406932A (zh) | 2020-10-22 | 2024-02-16 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| TW202300517A (zh) | 2021-03-12 | 2023-01-01 | 美商美國禮來大藥廠 | 抗類澱粉β抗體及其用途 |
| US20220389394A1 (en) | 2021-05-18 | 2022-12-08 | Gilead Sciences, Inc. | METHODS OF USING FLT3L-Fc FUSION PROTEINS |
| WO2022251048A1 (en) | 2021-05-24 | 2022-12-01 | Eli Lilly And Company | Anti-amyloid beta antibodies and uses thereof |
| WO2023081898A1 (en) | 2021-11-08 | 2023-05-11 | Alector Llc | Soluble cd33 as a biomarker for anti-cd33 efficacy |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| US6136310A (en) | 1991-07-25 | 2000-10-24 | Idec Pharmaceuticals Corporation | Recombinant anti-CD4 antibodies for human therapy |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US6750324B1 (en) | 1997-12-02 | 2004-06-15 | Neuralab Limited | Humanized and chimeric N-terminal amyloid beta-antibodies |
| US6761888B1 (en) | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| EP2082749A3 (en) | 2000-07-07 | 2010-06-30 | Bioarctic Neuroscience AB | Prevention and treatment of Alzheimer's disease |
| AU2001291096A1 (en) * | 2000-09-15 | 2002-03-26 | Coley Pharmaceutical Gmbh | Process for high throughput screening of CpG-based immuno-agonist/antagonist |
| PE20020574A1 (es) * | 2000-12-06 | 2002-07-02 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido amiloideo beta |
| US20060024302A1 (en) * | 2004-03-05 | 2006-02-02 | Ludwig Institute For Cancer Research | Chimeric anti-VEGF-D antibodies and humanized anti-VEGF-D antibodies and methods of using same |
| SE0401601D0 (sv) * | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| US7919086B2 (en) * | 2004-07-09 | 2011-04-05 | Chugai Seiyaku Kabushiki Kaisha | Anti-glypican 3 antibody |
| EP2298807A3 (en) * | 2004-07-30 | 2011-05-18 | Rinat Neuroscience Corp. | Antibodies directed against amyloid-beta peptide and methods using same |
| CA2582683A1 (en) * | 2004-10-01 | 2006-04-13 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Novel antibodies directed to the mammalian eag1 ion channel protein |
| EP1841455A1 (en) * | 2005-01-24 | 2007-10-10 | Amgen Inc. | Humanized anti-amyloid antibody |
| WO2007108755A1 (en) * | 2006-03-22 | 2007-09-27 | Gyros Patent Ab | Plex method |
| KR101413615B1 (ko) * | 2006-03-23 | 2014-07-18 | 바이오악틱 뉴로사이언스 에이비 | 인간 프로토피브릴에 선택적인 개선된 항체 및 이의 용도 |
| CN101622275B (zh) * | 2007-01-05 | 2013-11-06 | 苏黎世大学 | 提供疾患特异性结合分子和靶的方法 |
| CA2676049C (en) * | 2007-03-01 | 2018-04-10 | Symphogen A/S | Recombinant anti-epidermal growth factor receptor antibody compositions |
| LT2195023T (lt) | 2007-08-29 | 2018-06-25 | Sanofi | Humanizuoti anti-cxcr5 antikūnai, jų dariniai ir jų panaudojimas |
| CA2705582A1 (en) * | 2007-11-16 | 2009-05-22 | The Rockefeller University | Antibodies specific for the protofibril form of beta-amyloid protein |
| ES2633965T3 (es) * | 2008-07-08 | 2017-09-26 | Geneuro Sa | Uso terapéutico de ligando específico en enfermedades asociadas a MSRV |
| DK2406288T3 (en) * | 2009-03-10 | 2017-03-27 | Baylor Res Inst | ANTIGEN PRESENTING CELL-TARGETED VACCINES |
| CN102741295A (zh) * | 2009-03-10 | 2012-10-17 | 贝勒研究院 | 靶向抗原呈递细胞的抗病毒疫苗 |
| TWI508976B (zh) * | 2009-04-21 | 2015-11-21 | Univ Rockefeller | 對β－類澱粉蛋白之基原纖維形式具專一性之抗體 |
-
2009
- 2009-05-12 FR FR0953133A patent/FR2945538B1/fr not_active Expired - Fee Related
-
2010
- 2010-05-11 AU AU2010247215A patent/AU2010247215B2/en not_active Ceased
- 2010-05-11 CA CA2761665A patent/CA2761665A1/fr not_active Abandoned
- 2010-05-11 ES ES15160538.3T patent/ES2664409T3/es active Active
- 2010-05-11 KR KR1020117029577A patent/KR101783058B1/ko active IP Right Grant
- 2010-05-11 MX MX2011012060A patent/MX2011012060A/es active IP Right Grant
- 2010-05-11 BR BRPI1012853-0A patent/BRPI1012853B1/pt not_active IP Right Cessation
- 2010-05-11 SG SG2011085255A patent/SG176155A1/en unknown
- 2010-05-11 RS RS20150459A patent/RS54122B1/en unknown
- 2010-05-11 EP EP10728743.5A patent/EP2430049B1/fr active Active
- 2010-05-11 EA EA201171388A patent/EA028357B1/ru not_active IP Right Cessation
- 2010-05-11 AR ARP100101602A patent/AR076670A1/es active IP Right Grant
- 2010-05-11 PL PL10728743T patent/PL2430049T3/pl unknown
- 2010-05-11 PE PE2011001949A patent/PE20120906A1/es active IP Right Grant
- 2010-05-11 US US13/319,710 patent/US8614299B2/en active Active
- 2010-05-11 WO PCT/FR2010/050915 patent/WO2010130946A1/fr active Application Filing
- 2010-05-11 ES ES10728743.5T patent/ES2542757T3/es active Active
- 2010-05-11 DK DK10728743.5T patent/DK2430049T3/en active
- 2010-05-11 TW TW099115013A patent/TWI542360B/zh not_active IP Right Cessation
- 2010-05-11 JP JP2012510343A patent/JP2012526541A/ja active Pending
- 2010-05-11 LT LTEP15160538.3T patent/LT2977385T/lt unknown
- 2010-05-11 EP EP15160538.3A patent/EP2977385B1/fr active Active
- 2010-05-11 PT PT151605383T patent/PT2977385T/pt unknown
- 2010-05-11 DK DK15160538.3T patent/DK2977385T3/en active
- 2010-05-11 PL PL15160538T patent/PL2977385T3/pl unknown
- 2010-05-11 CN CN201080030434.6A patent/CN102459336B/zh not_active Expired - Fee Related
- 2010-05-11 SI SI201030968T patent/SI2430049T1/sl unknown
- 2010-05-11 HU HUE15160538A patent/HUE036737T2/hu unknown
- 2010-05-11 UA UAA201114656A patent/UA107574C2/ru unknown
- 2010-05-11 NZ NZ596540A patent/NZ596540A/xx not_active IP Right Cessation
- 2010-05-11 TW TW105112498A patent/TWI583791B/zh not_active IP Right Cessation
- 2010-05-11 MY MYPI2011005458A patent/MY159398A/en unknown
- 2010-05-11 MA MA34434A patent/MA33350B1/fr unknown
- 2010-05-11 EP EP16155574.3A patent/EP3050898B1/fr not_active Expired - Fee Related
- 2010-05-11 SI SI201031662T patent/SI2977385T1/en unknown
- 2010-05-11 PT PT107287435T patent/PT2430049E/pt unknown
- 2010-05-12 UY UY0001032633A patent/UY32633A/es active IP Right Grant
-
2011
- 2011-11-08 GT GT201100283A patent/GT201100283A/es unknown
- 2011-11-08 CR CR20110585A patent/CR20110585A/es unknown
- 2011-11-09 IL IL216237A patent/IL216237B/en active IP Right Grant
- 2011-11-10 TN TNP2011000571A patent/TN2011000571A1/fr unknown
- 2011-11-11 SV SV2011004058A patent/SV2011004058A/es active IP Right Grant
- 2011-11-11 CO CO11153627A patent/CO6460745A2/es active IP Right Grant
- 2011-11-11 ZA ZA2011/08301A patent/ZA201108301B/en unknown
- 2011-11-11 CL CL2011002831A patent/CL2011002831A1/es unknown
- 2011-11-11 NI NI201100195A patent/NI201100195A/es unknown
- 2011-11-11 EC EC2011011452A patent/ECSP11011452A/es unknown
-
2012
- 2012-08-13 HK HK12107898.4A patent/HK1167152A1/xx not_active IP Right Cessation
-
2013
- 2013-10-01 US US14/042,942 patent/US9382312B2/en active Active
-
2015
- 2015-07-14 CY CY20151100622T patent/CY1116842T1/el unknown
- 2015-07-14 HR HRP20150776TT patent/HRP20150776T1/hr unknown
- 2015-10-01 JP JP2015195617A patent/JP6310895B2/ja not_active Expired - Fee Related
-
2016
- 2016-06-02 US US15/171,708 patent/US10112991B2/en not_active Expired - Fee Related
-
2018
- 2018-03-27 CY CY20181100343T patent/CY1120413T1/el unknown
- 2018-03-27 HR HRP20180516TT patent/HRP20180516T1/hr unknown
- 2018-09-26 US US16/142,666 patent/US20190119365A1/en not_active Abandoned
- 2018-11-27 HR HRP20181985TT patent/HRP20181985T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20180516T1 (hr) | Humanizirana protutijela specifična za protofibrilni oblik amiloidnog-beta peptida | |
| RU2558301C2 (ru) | Полипептиды для связывания с "рецептором конечных продуктов гликирования", а также их композиции и способы, в которых они принимают участие | |
| JP6952827B2 (ja) | 血液脳関門輸送分子およびそれらの使用 | |
| HRP20191219T1 (hr) | Molekule protutijela koje imaju specifičnost za ljudski ox40 | |
| HRP20191342T1 (hr) | Anti-phf-tau antitijela i njihove upotrebe | |
| JP2010526028A5 (hr) | ||
| HRP20170254T1 (hr) | Humanizirana i kimerna monoklonska protutijela usmjerena na cd47 | |
| JP2014518883A5 (hr) | ||
| JP2017523786A5 (hr) | ||
| FI3378535T3 (fi) | Alfa-synukleiinin tunnistavia humanisoituja vasta-aineita | |
| JP2015533795A5 (hr) | ||
| HRP20140618T1 (hr) | Protutijela protiv beta-amiloidnog peptida | |
| JP2012501669A5 (hr) | ||
| WO2016077840A2 (en) | TfR SELECTIVE BINDING COMPOUNDS AND RELATED METHODS | |
| JP2012501670A5 (hr) | ||
| JP2017522891A5 (hr) | ||
| SI2802606T1 (en) | Improves the transfer of healing molecules through the hematoencephalic barrier | |
| JP2016529229A5 (hr) | ||
| JP2013515508A5 (hr) | ||
| JP2013539369A5 (hr) | ||
| WO2015191934A2 (en) | Blood-brain barrier (bbb) penetrating dual specific binding proteins for treating brain and neurological diseases | |
| JP2014510519A5 (hr) | ||
| JP2012530487A5 (hr) | ||
| JP2015518829A5 (hr) | ||
| RU2015126663A (ru) | Гуманизированное антитело против hmgb1 или антиген-связывающий фрагмент указанного антитела |